🚀 VC round data is live in beta, check it out!
Grace Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Grace Therapeutics and similar public comparables like LTR Pharma, Entera Bio, Dicot Pharma, Türk İlaç and more.
Grace Therapeutics Overview
About Grace Therapeutics
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Founded
2002
HQ
Employees
6
Website
Sectors
Financials (LTM)
EV
$40M
Grace Therapeutics Financials
Grace Therapeutics reported last 12-month revenue of — and negative EBITDA of ($10M).
In the same LTM period, Grace Therapeutics generated ($10M) in EBITDA losses and had net loss of ($15M).
Revenue (LTM)
Grace Therapeutics P&L
In the most recent fiscal year, Grace Therapeutics reported revenue of — and EBITDA of ($13M).
Grace Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($10M) | XXX | ($13M) | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($10M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Grace Therapeutics Stock Performance
Grace Therapeutics has current market cap of $63M, and enterprise value of $40M.
Market Cap Evolution
Grace Therapeutics' stock price is $4.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40M | $63M | 0.0% | XXX | XXX | XXX | $-0.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGrace Therapeutics Valuation Multiples
Grace Therapeutics trades at (4.0x) EV/EBITDA.
EV / Revenue (LTM)
Grace Therapeutics Financial Valuation Multiples
As of March 21, 2026, Grace Therapeutics has market cap of $63M and EV of $40M.
Equity research analysts estimate Grace Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grace Therapeutics has a P/E ratio of (4.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63M | XXX | $63M | XXX | XXX | XXX |
| EV (current) | $40M | XXX | $40M | XXX | XXX | XXX |
| EV/EBITDA | (4.0x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/EBIT | (2.4x) | XXX | (2.4x) | XXX | XXX | XXX |
| P/E | (4.1x) | XXX | (6.6x) | XXX | XXX | XXX |
| EV/FCF | (4.0x) | XXX | (2.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Grace Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Grace Therapeutics Margins & Growth Rates
Grace Therapeutics' revenue in the last fiscal year grew by —.
Grace Therapeutics' revenue per employee in the last FY averaged $0.0M.
Grace Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 16% | XXX | (22%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Grace Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Entera Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Dicot Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| BeyondSpring | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grace Therapeutics M&A Activity
Grace Therapeutics acquired XXX companies to date.
Last acquisition by Grace Therapeutics was on XXXXXXXX, XXXXX. Grace Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Grace Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGrace Therapeutics Investment Activity
Grace Therapeutics invested in XXX companies to date.
Grace Therapeutics made its latest investment on XXXXXXXX, XXXXX. Grace Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Grace Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Grace Therapeutics
| When was Grace Therapeutics founded? | Grace Therapeutics was founded in 2002. |
| Where is Grace Therapeutics headquartered? | Grace Therapeutics is headquartered in United States. |
| How many employees does Grace Therapeutics have? | As of today, Grace Therapeutics has over 6 employees. |
| Who is the CEO of Grace Therapeutics? | Grace Therapeutics' CEO is Prashant Kohli. |
| Is Grace Therapeutics publicly listed? | Yes, Grace Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Grace Therapeutics? | Grace Therapeutics trades under GRCE ticker. |
| When did Grace Therapeutics go public? | Grace Therapeutics went public in 2011. |
| Who are competitors of Grace Therapeutics? | Grace Therapeutics main competitors are LTR Pharma, Entera Bio, Dicot Pharma, Türk İlaç. |
| What is the current market cap of Grace Therapeutics? | Grace Therapeutics' current market cap is $63M. |
| Is Grace Therapeutics profitable? | No, Grace Therapeutics is not profitable. |
| What is the current EBITDA of Grace Therapeutics? | Grace Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Grace Therapeutics? | Current EBITDA multiple of Grace Therapeutics is (4.0x). |
| What is the current FCF of Grace Therapeutics? | Grace Therapeutics' last 12 months FCF is ($10M). |
| What is the current EV/FCF multiple of Grace Therapeutics? | Current FCF multiple of Grace Therapeutics is (4.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.